Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction...

Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk
Reduction of Prostate Cancer

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- The recent announcement of the
REDUCE trial results at the American Urological Association annual meeting in
Chicago brings optimism to the prostate cancer community as dutasteride
(Avodart), a drug used to treat benign prostatic hyperplasia, has shown to
lower by 23 percent the risk of prostate cancer in men with an increased risk
of the disease.

Men's Health Network looks forward to this becoming an additional tool in the
fight against prostate cancer.

The REDUCE trial is a placebo-controlled study that evaluates whether
dutasteride decreases the risk of biopsy-detectable prostate cancer.

As this disease continues to strike one in six American men, with African
American men having an incidence rate up to 60% higher than white men, it is
important that patients and physicians engage in a meaningful conversation
about prostate cancer, an individual's risk of getting the disease, and the
value of early detection and prevention.

Scott Williams, Vice President, Men's Health Network commented, "We
continually stress the importance for men to receive a baseline Prostate
Specific Antigen or PSA and physical exam of the prostate at age 40 and to
engage in a continual dialogue with their physician about their individual
risk and need for annual prostate exams. It could mean the difference between
living with the disease or dying from the disease."

PSA is currently the most effective tool physicians and patients have to
detect a disease that kills an estimated 28,000 men a year in the US.

In addition to the approximately 200,000 men who are diagnosed with prostate
cancer each year, we must remember that the disease can have a devastating
effect on entire families and communities. Spouses, significant others, and
children are often emotionally, financially, and physically strained and the
diagnosis reaches beyond the family to impact friendships, employers, and
churches.

"It is also important to note that families can impact the prevention and
early detection of prostate cancer," said Theresa Morrow of Women Against
Prostate Cancer. "Just a little encouragement from a spouse or family member
can get a man to the doctor for prostate screening."

The REDUCE trial is the first step in a paradigm shift in the way prostate
cancer is viewed, changing the conversation to focus on the value of
prevention and early detection of this deadly disease.

SOURCE Men's Health Network

Scott Williams of Men's Health Network, +1-202-543-6461 x101